Physiologically-Based Pharmacokinetic Modeling to Predict Methylphenidate Exposure Affected by Interplay Among Carboxylesterase 1 Pharmacogenetics, Drug-Drug Interactions, and Sex. [PDF]
Xiao J +5 more
europepmc +1 more source
Identification of regulatory variants of carboxylesterase 1 (CES1): A proof-of-concept study for the application of the Allele-Specific Protein Expression (ASPE) assay in identifying cis-acting regulatory genetic polymorphisms. [PDF]
Her L +6 more
europepmc +1 more source
Organophosphorus (OP) nerve agents are potent toxins that inhibit cholinesterases and produce a rapid and lethal cholin-ergic crisis. Development of protein-based therapeutics is be-ing pursued with the goal of preventing nerve agent toxicity and ...
Monika Wierdl +19 more
core +1 more source
Plasma Carboxylesterase 1 Predicts Methylphenidate Exposure: A Proof-of-Concept Study Using Plasma Protein Biomarker for Hepatic Drug Metabolism. [PDF]
Shi J +7 more
europepmc +1 more source
Prediction of Carboxylesterase 1-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic Models. [PDF]
Qian Y, Markowitz JS.
europepmc +1 more source
The carboxylesterase activity in the serum and liver of untreated Swiss-Webster mice, and in mice administered hepatotoxic doses of either CCl4 or paracetamol was studied.
Sergio A Villalobos +2 more
core +1 more source
Contributions of Cathepsin A and Carboxylesterase 1 to the Hydrolysis of Tenofovir Alafenamide in the Human Liver, and the Effect of CES1 Genetic Variation on Tenofovir Alafenamide Hydrolysis. [PDF]
Li J +5 more
europepmc +1 more source
Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers. [PDF]
Wang X +6 more
europepmc +1 more source

